Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 1-Year Low – Time to Sell?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week low on Friday . The company traded as low as $272.00 and last traded at $271.6850, with a volume of 390019 shares changing hands. The stock had previously closed at $283.15.

Analyst Ratings Changes

Several brokerages have issued reports on ALNY. Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a report on Friday, July 10th. Bank of America lowered their target price on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. HC Wainwright increased their target price on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $455.31.

Alnylam Pharmaceuticals Trading Down 5.5%

The stock has a 50-day simple moving average of $294.16 and a 200 day simple moving average of $321.11. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company has a market cap of $35.71 billion, a price-to-earnings ratio of 73.08 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the prior year, the firm posted ($0.44) earnings per share. The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.26 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALNY. MV Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $27,000. Golden State Wealth Management LLC boosted its stake in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the last quarter. Finally, Manchester Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 72 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.